211 related articles for article (PubMed ID: 37510750)
1. A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study.
Majewski S; Białas AJ; Barczyk A; Batura-Gabryel H; Buchczyk M; Doboszyńska A; Górska K; Grabowska-Skudlarz L; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krawczyk M; Krenke R; Lewandowska K; Mackiewicz B; Martusewicz-Boros MM; Milanowski J; Noceń-Piskorowska M; Nowicka A; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Stachura T; Tomczak M; Tomkowski W; Trzaska-Sobczak M; Ziora D; Żołnowska B; Piotrowski WJ
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510750
[TBL] [Abstract][Full Text] [Related]
2. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
[TBL] [Abstract][Full Text] [Related]
4. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
5. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
Ogura T; Inoue Y; Azuma A; Homma S; Kondoh Y; Tanaka K; Ochiai K; Sugiyama Y; Nukiwa T
Adv Ther; 2023 Apr; 40(4):1474-1493. PubMed ID: 36692681
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.
Nakamura M; Okamoto M; Fujimoto K; Ebata T; Tominaga M; Nouno T; Zaizen Y; Kaieda S; Tsuda T; Kawayama T; Hoshino T
Ann Transl Med; 2019 Jun; 7(12):262. PubMed ID: 31355229
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
9. Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study.
Ruaro B; Salotti A; Reccardini N; Kette S; Da Re B; Nicolosi S; Zuccon U; Confalonieri M; Mondini L; Pozzan R; Hughes M; Confalonieri P; Salton F
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256952
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
Sakamoto N; Hamada N; Okamoto M; Tobino K; Ichiyasu H; Ishii H; Ichikado K; Morimoto S; Hosogaya N; Mukae H
BMJ Open; 2021 Jun; 11(6):e047249. PubMed ID: 34187824
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.
Tzouvelekis A; Karampitsakos T; Kontou M; Granitsas A; Malliou I; Anagnostopoulos A; Ntolios P; Tzilas V; Bouros E; Steiropoulos P; Chrysikos S; Dimakou K; Koulouris N; Bouros D
Pulm Pharmacol Ther; 2018 Apr; 49():61-66. PubMed ID: 29366978
[TBL] [Abstract][Full Text] [Related]
12. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.
Toellner H; Hughes G; Beswick W; Crooks MG; Donaldson C; Forrest I; Hart SP; Leonard C; Major M; Simpson AJ; Chaudhuri N
Clin Transl Med; 2017 Nov; 6(1):41. PubMed ID: 29101500
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy.
Ruaro B; Gandin I; Pozzan R; Tavano S; Bozzi C; Hughes M; Kodric M; Cifaldi R; Lerda S; Confalonieri M; Baratella E; Confalonieri P; Salton F
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259452
[TBL] [Abstract][Full Text] [Related]
14. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Podolanczuk AJ; Cottin V
Adv Ther; 2023 May; 40(5):2038-2050. PubMed ID: 36928494
[TBL] [Abstract][Full Text] [Related]
15. Real world efficacy and safety of nintedanib in idiopathic pulmonary fibrosis: A single center, observational study from India.
Talwar D; Prajapat DK; Talwar D
Lung India; 2022; 39(1):27-33. PubMed ID: 34975049
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
17. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.
Komatsu M; Yamamoto H; Ichiyama T; Kawakami S; Uehara T; Yoshikawa Y; Kitaguchi Y; Ushiki A; Yasuo M; Hanaoka M
PLoS One; 2022; 17(2):e0262795. PubMed ID: 35113907
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis.
Hirasawa Y; Abe M; Terada J; Sakayori M; Suzuki K; Yoshioka K; Kawasaki T; Tsushima K; Tatsumi K
Pulm Pharmacol Ther; 2020 Jun; 62():101917. PubMed ID: 32205281
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib for Idiopathic Pulmonary Fibrosis.
Tepede A; Yogaratnam D
J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
